Michael Aberman - Regeneron Pharmaceuticals Vice President - Strategy

REGN -- USA Stock  

USD 285.89  4.27  1.52%

  President
Dr. Michael Aberman, M.D., is Senior Vice President Strategy and Investor Relation of the Company. He served as Vice President, Strategy and Investor Relations. Prior to joining the Company, he spent six years as a Wall Street analyst covering the biotechnology industry. From March 2006 until joining the Company, he was Director and Senior Biotechnology Analyst at Credit Suisse. Prior to that, from March 2004 to March 2006, he worked as a Biotechnology Analyst at Morgan Stanley, Inc. From February 2002 to March 2004, Dr. Aberman was Director of Business Development at Antigenics Inc., an oncologyfocused biotechnology company
Age: 45  President Since 2015  MBA    
914-847-7000  http://www.regeneron.com
Aberman received his M.D. with honors from the University of Toronto and his M.B.A. from the Wharton School of the University of Pennsylvania.

Management Efficiency

The company has return on total asset (ROA) of 11.57 % which means that it generated profit of $11.57 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 24.43 % meaning that it created $24.43 on every $100 dollars invested by stockholders.
The company currently holds 711.3M in liabilities with Debt to Equity (D/E) ratio of 7.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Sandra BeatyZoetis
2012
Svend AndersenPerrigo Company plc
2017
Ganadhish KamatDr Reddys Laboratories Ltd
2016
Charles WagnerVertex Pharmaceuticals Incorpor
2019
Thomas GraneyVertex Pharmaceuticals Incorpor
2017
Catherine KnuppZoetis
2012
Kristin PeckZoetis
2018
Paul SilvaVertex Pharmaceuticals Incorpor
2019
Charles MilsteinVertex Pharmaceuticals Incorpor
2017
Glenn DavidZoetis
2016
Reshma KewalramaniVertex Pharmaceuticals Incorpor
2018
John HendricksonPerrigo Company plc
2016
Jeffrey NeedhamPerrigo Company plc
2009
Clinton LewisZoetis
2018
Paul WeningerPerrigo Company plc
2015
Thomas FarringtonPerrigo Company plc
2015
Grainne QuinnPerrigo Company plc
2016
Amit SachdevVertex Pharmaceuticals Incorpor
2017
Umang VohraDr Reddys Laboratories Ltd
2013
Scott JamisonPerrigo Company plc
2011
Joyce LeeZoetis
2012

Entity Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7549 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 7,549 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Did you try this?

Run Focused Opportunities Now

   

Focused Opportunities

Build portfolios using our predefined set of ideas and optimize them against your investing preferences
All  Next Launch Module

Currently Active Assets on Macroaxis

MSFT   
Purchased over 20 shares of
1 hour ago
Traded for 135.34
VMW   
Purchased a lot of shares of
1 hour ago
Traded for 155.87
GM   
Purchased over 70 shares of
1 hour ago
Traded for 35.56
V   
Purchased few shares of
1 hour ago
Traded for 174.95
CRM   
Purchased a lot of shares of
1 hour ago
Traded for 153.01
Additionally take a look at Your Equity Center. Please also try Headlines Timeline module to stay connected to all market stories and filter out noise. drill down to analyze hype elasticity.
Search macroaxis.com